Photo from wikipedia
Anlotinib is a third‐line or further therapy for advanced non‐small‐cell lung cancer (NSCLC). However, the lack of simple biomarkers to predict the curative effect of anlotinib creates significant unmet needs… Click to show full abstract
Anlotinib is a third‐line or further therapy for advanced non‐small‐cell lung cancer (NSCLC). However, the lack of simple biomarkers to predict the curative effect of anlotinib creates significant unmet needs in exploring the markers. This study aimed to explore the relationship between the prognostic nutritional index (PNI) and its variations and efficacy of anlotinib.
Keywords:
lung cancer;
non small;
prognostic nutritional;
small cell;
advanced non;
cell lung
Journal Title: Journal of Clinical Laboratory Analysis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Laboratory Analysis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!